title: Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.
abstract: BACKGROUND
  Animal studies have suggested that thiazolidinediones (TZDs) have antirestenotic properties. However, human data are lacking. The goal of this single-center study was to assess the target vessel revascularization (TVR) rate following percutaneous coronary intervention (PCI) among diabetic patients according to TZD use.
  
  
  METHODS
  A total of 325 consecutive diabetic patients who underwent PCI between January 2000 and December 2001 were included in the analysis. Among them, 82 patients were on TZD and 243 patients were on other hypoglycemic regimens. All patients were treated with stents and platelet glycoprotein IIb/IIIa inhibitors at the time of intervention. TVR and death/myocardial infarction/TVR were assessed at 1 year.
  
  
  RESULTS
  TZD patients were more likely to be younger, male and have hyperlipidemia. TVR occurred in 36.6% of TZD patients compared with 23.9% of non-TZD patients (p=0.04). One-year death, myocardial infarction and TVR occurred in 41.1% of TZD patients compared with 30.8% of non-TZD patients (p=0.04).
  
  
  CONCLUSIONS
  In this retrospective analysis, TZD therapy did not decrease the need for repeat revascularization following PCI. Prospective randomized studies are warranted.
authors: Department of Cardiology, Loyola University Medical Center, Maywood, IL 60153, USA. lcho@lumc.edu
authors: Leslie
authors: L
authors: Cho
authors: Bruce E
authors: BE
authors: Lewis
authors: Lowell H
authors: LH
authors: Steen
authors: Ferdinand S
authors: FS
authors: Leya
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002423:Cause of Death; D003326:Coronary Circulation / Q000187:drug effects*; D023921:Coronary Stenosis / Q000401:mortality / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000401:mortality / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000401:mortality / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality; D000077205:Pioglitazone; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D000077154:Rosiglitazone; D015607:Stents; D015996:Survival Rate; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D007004:Hypoglycemic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone